John A. Katzenellenbogen, Chairman of the SAB, received a Ph.D. in Organic Chemistry from Harvard University and holds the Swanlund Professorship of Chemistry at the University of Illinois, Urbana, where his research interests involve organic and inorganic chemistry, radiochemistry, biochemistry and molecular biology. He received the E.B. Hershberg Award for Important Discoveries in Medicinally Active Substances at the American Chemical Society Meeting in 2007, and has received many other awards.
Frank H. Eeckman received his M.D. from the University of Ghent in Belgium, where he completed his residency in Neurology. He later received a Ph.D. in Physiology from the University of California, Berkeley, and served as the Senior Director of IT and Bioinformatics at GeneTrace Systems. He is currently the Chief Scientific Officer of Centient Consulting in Berkeley, of which he was a co-founder.
Robert S. Negrin received his M.D. from Harvard University and currently serves as Director, Bone Marrow Transplant Program and Professor of Medicine, Stanford Medical School, where his research concerns the biology of cells capable of inducing or suppressing graft vs. host disease as well as cells promoting a graft vs. tumor effect. Dr. Negrin previously served as the President of the American Society for Blood and Marrow Transplantation.
Ralph W. Niven received his Ph.D. in Pharmaceutical Sciences from the University of Kentucky. He previously served as a Research Scientist at Amgen, as VP for Development at Advanced Inhalation Research (AIR) and as Senior VP for Preclinical Development at Discovery Laboratories. He is currently the Chief Technical Officer of APT Pharmaceuticals, Inc. in Foster City, CA, and serves on the Scientific Advisory Board of Nanosphere Corporation.
Barry M. Sherman received his M.D. from the University of Michigan and is board-certified in internal medicine and endocrinology. He was a Professor of Medicine and Endocrinology at the University of Iowa and currently serves as the Executive Vice President for Development at BiPar Sciences, Inc, Brisbane, CA. He was the first Senior VP and Chief Medical Officer of Genentech and later served as the President and CEO of Anergen, Inc.
Michael G. Shulman received his M.D. from Columbia University and was in private practice in Internal Medicine, Nephrology and Hypertension for 17 years before entering the pharmaceutical industry. He has held positions or served as a consultant to Sandoz, Syntex, Genentech, Anergen, Cellerant Therapeutics and Alza Corporation, among others. His consultancy in San Francisco, CA, is called BioMedical Resources for Global Drug Development.